Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin and its effect on heart failure in type 2 diabetes (EFFORT)
2016-000214-30Phase 4Completed
- Sponsor
- Universitätsklinikum Freiburg
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in heart failure (HF), heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF) and 1 more comparing Empagliflozin with Placebo (2 arms). Started May 2016; status: completed.
02
Drugs
empagliflozin
03
Conditions
heart failure (HF)heart failure with reduced ejection fraction (HFrEF)heart failure with preserved ejection fraction (HFpEF)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2016-000214-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000214-30.